(R)-1-ethyl-3-hydroxypyrrolidine | 216666-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-1-ethyl-3-hydroxypyrrolidine
• 英文别名: (3R)-1-(2-aminoethyl)pyrrolidin-3-ol；(R)-1-ethyl-3-pyrrolidinol；(3R)-1-ethylpyrrolidin-3-ol
• CAS: 216666-93-2
• 化学式: C₆H₁₃NO
• 分子量: 115.175
• InChiKey: IDBNECMSCRAUNU-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-1-ethyl-3-hydroxypyrrolidine 在 lithium aluminium tetrahydride 、 迭氮酸 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 乙醚 、 苯 为溶剂， 反应 8.0h， 生成 (S)-1-ethyl-3-aminopyrrolidine
  参考文献：
  名称：

  Structure-Selectivity Relationship in Alkyllithium−Aldehyde Condensations Using 3-Aminopyrrolidine Lithium Amides as Chiral Auxiliaries

  摘要：

  A nonracemizing route to a set of chiral 3-aminopyrrolidines, based on 4-hydroxy-(L)-proline, is described. The induction potential of the lithium amides derived from these diamines has then been investigated in the asymmetric addition of alkyllithium compounds onto various aldehydes. Enantiomeric excesses up to 76% have been obtained in the case of the condensation of n-butyllithium onto o-tolualdehyde under standard experimental conditions (THF, -78 degrees C). Interestingly, the presence of a second asymmetric center, such as an alpha-methylbenzyl group, on the lateral 3-amino group gives access, according to its configuration, to one or the other of the 1-o-tolylpentan-1-ol enantiomers.

  DOI：

  10.1021/jo9810260
• 作为产物：
  描述：

  (R)-3-吡咯烷醇 、 乙酰氯 在 吡啶 、 lithium aluminium tetrahydride 作用下， 以 二氯甲烷 、 四氢呋喃 为溶剂， 反应 9.0h， 以83%的产率得到(R)-1-ethyl-3-hydroxypyrrolidine
  参考文献：
  名称：

  Structure-Selectivity Relationship in Alkyllithium−Aldehyde Condensations Using 3-Aminopyrrolidine Lithium Amides as Chiral Auxiliaries

  摘要：

  A nonracemizing route to a set of chiral 3-aminopyrrolidines, based on 4-hydroxy-(L)-proline, is described. The induction potential of the lithium amides derived from these diamines has then been investigated in the asymmetric addition of alkyllithium compounds onto various aldehydes. Enantiomeric excesses up to 76% have been obtained in the case of the condensation of n-butyllithium onto o-tolualdehyde under standard experimental conditions (THF, -78 degrees C). Interestingly, the presence of a second asymmetric center, such as an alpha-methylbenzyl group, on the lateral 3-amino group gives access, according to its configuration, to one or the other of the 1-o-tolylpentan-1-ol enantiomers.

  DOI：

  10.1021/jo9810260

文献信息

• [EN] STRAD-BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS DE LIAISON À STRAD ET LEURS UTILISATIONS
  申请人：UNIV CALIFORNIA

  公开号：WO2021155004A1

  公开（公告）日：2021-08-05

  Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.

  披露的内容包括，但不限于，用于结合STRAD假激酶的化合物及其用途。
• JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
  申请人：Incyte Corporation

  公开号：US20150246046A1

  公开（公告）日：2015-09-03

  This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).

  本发明涉及JAK1选择性抑制剂，特别是吡咯[2,3-d]嘧啶和吡咯[2,3-b]吡啶衍生物，以及它们在治疗骨髓增生异常综合征（MDS）中的应用。
• [EN] AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION<br/>[FR] AZA-OXO-INDOLES POUR LE TRAITEMENT ET LA PROPHYLAXIE DE L'INFECTION À VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014184163A1

  公开（公告）日：2014-11-20

  The invention provides compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, W1, W2, W3, A and X are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有以下一般式的化合物：其中R1、R2、R3、R4、R5、R6、W1、W2、W3、A和X如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。
• Substituted 3-Amino-Pyrrolidino-4-Lactams
  申请人：Piotrowski David W.

  公开号：US20070299076A1

  公开（公告）日：2007-12-27

  The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R 1 , n and R 2 are as described herein; compositions thereof; and uses thereof.

  这项发明提供了式（1）的化合物，以及其药用可接受的盐，其中R1、n和R2如本文所述；以及它们的组合物；以及它们的用途。
• [EN] FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES FUMAGILLOL, ET PROCÉDÉS CORRESPONDANTS DE FABRICATION ET D'UTILISATION
  申请人：ZAFGEN INC

  公开号：WO2017027684A1

  公开（公告）日：2017-02-16

  Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  本文披露了富马吉醇化合物及其在治疗医学疾病（如肥胖症）中的用途方法。提供了富马吉醇化合物的药物组合物和制备方法。这些化合物被认为具有对蛋氨酸氨肽酶2的活性。